Improving representation of African American patients in multiple myeloma research is essential to preventing outcome disparities in this population, according to a spotlight session at ASH Annual Meeting and Exposition.
“The incidence of multiple myeloma in African Americans is two- to threefold higher and mortality is more than double compared to Caucasians,” Srinivas S. Devarakonda, MD, associate professor of hematology at The Ohio State University, said. “They comprise 20% to 22% of the population with multiple myeloma, yet their representation in clinical trials is less
